BridgeMD
Impact of Angiotensin Receptor Blocker in aortic stenosis
EU CTIS ID: 2024-518389-28-00
What this study is testing
This study is intended to investigate the effect of angiotensin receptor blockers on mild to moderate aortic stenosis.
- Therapeutic use (Phase IV)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Patients with mild-moderate aortic stenosis (peak aortic jet velocity ≥2.5 and <4m/s).
- Age ≥ 20 ≤ 85 years
- Left ventricular ejection fraction ≥50%
- Systolic blood pressure ≥100 mmHg
- Signed informed consent
You likely can't join if
- More than mild aortic or mitral regurgitation, or mitral stenosis
- Current use of renin-angiotensin system medication or Aliskiren in patiens with arterial hypertension and diabetes mellitus or arterial hypertension and chronic kidney disease stage 4-5 (estimated glomerular filtration rate <30 ml/min/1.73m2)
- Known allergy or intolerance to Angiotensin-receptor-blockers, poorly controlled blood pressure
- Renal dysfunction (glomerular filtration rate <30ml/min/1.73 m2) or chronic hyperkalemia (P-potassium ≥5.5 mmol/l)
- Hepatic failure, cirrhosis, hepatitis or history of hepatic impairment
- Newly diagnosed (<2 months) or poorly controlled diabetes; HbA1c >86 mmol/mol (>10%)
See the full eligibility criteria
- Patients with mild-moderate aortic stenosis (peak aortic jet velocity ≥2.5 and <4m/s).
- Age ≥ 20 ≤ 85 years
- Left ventricular ejection fraction ≥50%
- Systolic blood pressure ≥100 mmHg
- Signed informed consent
- More than mild aortic or mitral regurgitation, or mitral stenosis
- Current use of renin-angiotensin system medication or Aliskiren in patiens with arterial hypertension and diabetes mellitus or arterial hypertension and chronic kidney disease stage 4-5 (estimated glomerular filtration rate <30 ml/min/1.73m2)
- Known allergy or intolerance to Angiotensin-receptor-blockers, poorly controlled blood pressure
- Renal dysfunction (glomerular filtration rate <30ml/min/1.73 m2) or chronic hyperkalemia (P-potassium ≥5.5 mmol/l)
- Hepatic failure, cirrhosis, hepatitis or history of hepatic impairment
- Newly diagnosed (<2 months) or poorly controlled diabetes; HbA1c >86 mmol/mol (>10%)
- Pre-existing obstructive coronary artery disease with CCS III-IV angina or recent myocardial infarction (<3 months)
- Pregnant or lactating women. Fertile women without highly effective birth control method. Patients unable to read, understand or sign research consent
The study team makes the final eligibility decision.
Where it's taking place
- Canada
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 65+ years, 18-64 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Canada. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.